Search
Streptococcus pneumoniae type 15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB16717ApprovedInvestigationalStreptococcus pneumoniae type 15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae … * serotype 15B individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β197).
Streptococcus pneumoniae type 23A capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB19348ApprovedInvestigationalStreptococcus pneumoniae type 23A capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of _Streptococcus pneumoniae … _ serotype 23A individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of _Corynebacterium diphtheriae_ strain C7 (β197).
Streptococcus pneumoniae type 5 capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB10295ApprovedInvestigationalserotype 5 individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β197). … Streptococcus pneumoniae type 5 capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae*
Synonyms: Streptococcus pneumoniae serotype 5 capsular antigen diphtheria CRM197 protein conjugate vaccine, Streptococcus pneumoniae type 5 capsular polysaccharide diphtheria CRM197 protein conjugate antigenInfigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawn[A235174] Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy. … By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsMibefradil
go.drugbank.com/drugs/DB01388ApprovedWithdrawnMibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSaprisartan
go.drugbank.com/drugs/DB01347ExperimentalIt is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism [A14009]. … The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan.
Categories: Agents Acting on the Renin-Angiotensin System, Heterocyclic Compounds, 2-RingSugammadex
go.drugbank.com/drugs/DB06206ApprovedInvestigationalSugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. … Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015.
Categories: Compounds used in a research, industrial, or household settingProducts: BRIDION® 200 MG/2 ML SOLUCIÓN PARA INYECCIÓN, MIGAD-XMycophenolic acid
go.drugbank.com/drugs/DB01024ApprovedInvestigational[A249190] [Mycophenolate mofetil], a prodrug of mycophenolic acid, is also prescribed to transplant recipients to prevent organ rejection.[L42020] … [A249175] This regimen can be used in place of the older anti-proliferative [azathioprine] due to its stronger immunosuppressive potency.
Synonyms: (e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acidCategories: Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexApadamtase alfa
go.drugbank.com/drugs/DB15164ApprovedInvestigational[A262076] It may be inherited (congenital TTP; cTTP) or acquired due to autoantibodies (immune-mediated TTP; iTTP), although cTTP accounts for <5% of all cases of TTP. … for cleaving large von Willebrand factor multimers and preventing the formation of microthrombi - this deficiency in ADAMTS13 is responsible for the microangiopathic complications associated with cTTP
Synonyms: Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifsSunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalOn January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). … Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic IndexProducts: DOSTINIB® 25MG, DOSTINIB® 50MG